Mohamed Loqman A, Kaddoumi Amal
Department of Basic Pharmaceutical Science, School of Pharmacy, University of Louisiana at Monroe. 1800 Bienville Dr., Monroe, LA.
J Pharm Pharm Sci. 2014;17(3):427-38. doi: 10.18433/j3801t.
PURPOSE. The knowledge of hepatic disposition kinetics of tacrine, a first cholinesterase inhibitor was approved by FDA for the treatment of Alzheimer's disease (AD), would help to understand its hepatotoxicity, its therapeutic effect, and improve the management of patients with AD. The current study aims to characterize tacrine hepatic transport kinetics and study the role of organic cation transporters (OCTs), P-glycoprotein (P-gp) and multidrug resistance-associated protein (MRP2) in tacrine sinusoidal uptake and biliary excretion. METHODS. Modulation of tacrine hepatic uptake and efflux, biliary excretion index (BEI%), were performed in sandwich-cultured primary rat hepatocytes (SCHs) using transporters inhibitors. Conformation of the integrity of SCHs model was established by capturing images with light-contrast and fluorescence microscopy. RESULTS. Tacrine uptake in SCHs was carrier-mediated process and saturable with apparent Km of 31.5±9.6 µM and Vmax of 908±72 pmol/min/mg protein. Tetraethyl ammonium (TEA), cimetidine and verapamil significantly reduced tacrine uptake with more pronounced effect observed with verapamil which caused 3-fold reduction in tacrine uptake, indicating role for OCTs. Tacrine has a biliary excretion in SCHs with maximum BEI% value of 22.9±1.9% at 10 min of incubation. Addition of MK571 and valspodar decreased the BEI% of tacrine by 40 and 60% suggesting roles for canalicular MRP2 and P-gp, respectively. CONCLUSIONS. Our results show that in addition to metabolism, tacrine hepatic disposition is carrier-mediated process mediated by sinusoidal OCTs, and canalicular MRP2 and P-gp.
目的。他克林是首个被美国食品药品监督管理局(FDA)批准用于治疗阿尔茨海默病(AD)的胆碱酯酶抑制剂,了解其肝脏处置动力学将有助于理解其肝毒性、治疗效果,并改善AD患者的管理。本研究旨在表征他克林的肝脏转运动力学,并研究有机阳离子转运体(OCTs)、P-糖蛋白(P-gp)和多药耐药相关蛋白(MRP2)在他克林肝窦摄取和胆汁排泄中的作用。方法。在三明治培养的原代大鼠肝细胞(SCHs)中使用转运体抑制剂调节他克林的肝脏摄取、外排和胆汁排泄指数(BEI%)。通过光学显微镜和荧光显微镜拍摄图像来确定SCHs模型的完整性。结果。他克林在SCHs中的摄取是载体介导的过程,具有饱和性,表观Km为31.5±9.6 μM,Vmax为908±72 pmol/min/mg蛋白。四乙铵(TEA)、西咪替丁和维拉帕米显著降低他克林的摄取,维拉帕米的作用更明显,导致他克林摄取降低3倍,表明OCTs发挥了作用。他克林在SCHs中有胆汁排泄,孵育10分钟时最大BEI%值为22.9±1.9%。添加MK571和环孢素A分别使他克林的BEI%降低40%和60%,表明分别是胆小管MRP2和P-gp发挥了作用。结论。我们的结果表明,除代谢外,他克林的肝脏处置是由肝窦OCTs、胆小管MRP2和P-gp介导的载体介导过程。